^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cytarabine

    i
    Other names: HiDAC, LDAC
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    Related drugs:
    2d
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    4d
    GANCE: Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML (clinicaltrials.gov)
    P2, N=25, Recruiting, First Affiliated Hospital of Zhejiang University | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Dec 2028
    Enrollment open • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)
    |
    FLT3-ITD mutation
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine
    4d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    4d
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)
    4d
    Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=65, Completed, First Affiliated Hospital of Zhejiang University | Recruiting --> Completed | N=30 --> 65 | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    cytarabine • cladribine • Synribo (omacetaxine mepesuccinate)
    8d
    Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome (clinicaltrials.gov)
    P2, N=26, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cytarabine • Starasid (cytarabine ocfosfate)
    9d
    A clinical study on the use of thiotepa in combination with semustine and cytarabine for conditioning of autologous hematopoietic stem cell transplantation in primary central nervous system lymphoma (ChiCTR2500111944)
    P=N/A, N=22, Not yet recruiting, Henan Provincial People's Hospital; Henan Provincial People's Hospita,medical
    New trial
    |
    CD34 (CD34 molecule)
    |
    cytarabine • thiotepa
    9d
    Clinical Study of Selinoxor-Based Chemotherapy with Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells (ChiCTR2500115114)
    P=N/A, N=71, Recruiting, Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o
    New trial
    |
    cytarabine • hydroxyurea
    10d
    Identification of Tumor- and Immunosuppression-Driven Glioblastoma Subtypes Characterized by Clinical Prognosis and Therapeutic Targets. (PubMed, Curr Issues Mol Biol)
    We predicted potential therapeutic small molecular drugs by targeting subtype-specific oncogenic pathways and validated drug sensitivity (C1-GBM: Methotrexate and Cisplatin; C2-GBM: Cytarabine) by assessing IC50 values against GBM cell lines (divided into C1/C2 subtypes based on the nine hub genes) from the Genomics of Drug Sensitivity in Cancer database. This study introduces a pathway-based prognostic molecular classification of GBM with "hot" (C1-GBM) and "inherent driving" (C2-GBM) tumor subtypes, providing a prediction model based on hub biomarkers and potential therapeutic targets for treatments.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • cytarabine • methotrexate
    11d
    Myeloid sarcoma transformed from myeloproliferative neoplasm: A case report and review of literature. (PubMed, World J Clin Oncol)
    Cases of myelofibrosis transforming into MS are extremely rare. The TP53 mutation is a key molecular marker associated with poor tumor prognosis. Because it can be easily mistaken for other tumors, it is crucial to perform relevant examinations and establish a clear diagnosis as early as possible. This facilitates the timely formulation of an appropriate treatment plan and may help prolong the patient's life.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • idarubicin hydrochloride
    12d
    Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions. (PubMed, Cancers (Basel))
    By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.
    Review • Journal • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    cytarabine • midostaurin • melphalan
    12d
    ATACC AML: Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=26, Completed, Baylor College of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • atovaquone